



Form PTO-1449 (modified)

Atty. Docket No.  
UTSC:664USC2Serial No.  
10/672,142

List of Patents and Publications for Applicant's

Applicant  
David Yang *et al.*

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:  
September 26, 2003Group:  
1616 1618U.S. Patent Documents  
*See Page 1*Foreign Patent Documents  
*See Page 1*Other Art  
*See Page 1*

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
<i>[initials]</i>	A44	4,279,992	7/21/81	Boguslaski <i>et al.</i>	435	7	10/23/79
	A45	4,789,542	12/06/88	Goodman and Knapp, Jr.	424	1.1	4/29/86
	A46	4,824,659	4/25/89	Hawthorne	424	1.1	6/07/85
	A47	5,013,556	5/07/91	Woodle <i>et al.</i>	424	450	10/20/89
	A48	5,356,793	10/18/94	Koezuka <i>et al.</i>	435	32	2/01/91
	A49	5,643,883	6/01/97	Marchase and Darbha	514	23	1/19/95
	A50	5,688,487	11/18/97	Linder <i>et al.</i>	424	1.65	6/06/95
	A51	5,834,266	11/10/98	Crabtree <i>et al.</i>	435	172.3	8/18/94
	A52	5,877,289	3/02/99	Thorpe and Edgington	530	387.1	6/07/95
<i>[initials]</i>	A53	5,891,468	4/06/99	Martin and Zalipsky	424	450	10/10/97
	A54	6,033,884	3/07/00	Woo <i>et al.</i>	435	172.3	12/14/93
<i>[initials]</i>	A55	6,054,436	4/25/00	Crabtree <i>et al.</i>	514	31	5/29/98

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
<i>[initials]</i>	B11	WO 98/08859	3/05/98	WIPO			English

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>[initials]</i>	C340	Boersma <i>et al.</i> , "Quantification of apoptotic cells with fluorescein isothiocyanate-labeled annexin V in Chinese hamster ovary cell cultures treated with cisplatin," <i>Cytometry</i> , 24:123-130, 1996.
<i>[initials]</i>	C341	Cafaggi <i>et al.</i> , "Synthesis and antitumor activity of a new cis-diammineplatinum (III) complex containing procaine hydrochloride," <i>Anticancer Research</i> , 12:2285-2292, 1992.

25497767.1

EXAMINER:

DATE CONSIDERED: 1/4/07

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609. DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC2	Serial No. 10/672,142
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: 1616 1618
U.S. Patent Documents See Page 1	Foreign Patent Documents See Page 1	Other Art See Page 1	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C342	Cammissuli <i>et al.</i> , "SDZ 281-977: a modified partial structure of lavendustin A that exerts potent and selective antiproliferative activities in vitro and in vivo," <i>Int J Cancer</i> , 65:351-359, 1996.
	C343	Chakrabarti <i>et al.</i> , "Interaction of the antitumor antibiotic chromomycin A3 with glutathione, a sulfhydryl agent, and the effect upon its DNA binding properties," <i>Biochemical Pharmacology</i> , 56:1471-1479, 1998.
	C344	Connors, "Anticancer drug development: the way forward," <i>The Oncologist</i> , 1:180-181, 1996.
	C345	Guo and Gallo, "Selective protection of 2', 2'-difluorodeoxycytidine (Gemcitabine)," <i>J Org Chem</i> , 64:8319-8322, 1999.
	C346	Hirsch <i>et al.</i> , "PK11195, a ligand of the mitochondrial benzodiazepine receptor, facilitates the induction of apoptosis and reverses Bcl-2-mediated cytoprotection," <i>Experimental Cell Research</i> , 241:426-434, 1998.
	C347	Hjarnaa <i>et al.</i> , "CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo," <i>Cancer Res.</i> , 59:5751-5757, 1999.
	C348	Inoue <i>et al.</i> , "Evaluation of In-111 DTPA-paclitaxel scintigraphy to predict response on murine tumors to paclitaxel," <i>Annals of Nuclear Medicine</i> , 13(3):169-174, 1999.
	C349	Jiang <i>et al.</i> , "Antitumor activity of didemnin B in the human tumor stem cell assay," <i>Cancer Chemother Pharmacol</i> , 11:1-4, 1983.
	C350	Jiang <i>et al.</i> , "3-(Iodoacetamido)-benzoylurea: a novel cancericidal tubulin ligand that inhibits microtubule polymerization, phosphorylates bcl-2, and induces apoptosis in tumor cells," <i>Cancer Res.</i> , 58:5389-5395, 1998.
	C351	LeClerc and Cedergren, "Modeling RNA-ligand interactions: the rev-binding element RNA-aminoglycoside complex," <i>J Med Chem</i> , 41:175-182, 1998.
	C352	Lundberg <i>et al.</i> , "Conjugation of an anti-B-cell lymphoma monoclonal antibody, LL2, to long-circulating drug-carrier lipid emulsions," <i>J Pharm Pharmacol</i> , 51:1099-1105, 1999.
	C353	McGahon <i>et al.</i> , "Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system," <i>British Journal of Haematology</i> , 101:539-547, 1998.
	C354	Meyer <i>et al.</i> , "Tryptophan hydrolase antibodies used in the diagnosis of carcinoid," <i>Hepato-Gastroenterology</i> , 45:1522-1526, 1998.

25497767.1

EXAMINER:

DATE CONSIDERED: 1/4/07

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)		Atty. Docket No. UTSC:664USC2	Serial No. 10/672,142
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant David Yang <i>et al.</i>	
		Filing Date: September 26, 2003	Group: 1616 <i>1618</i>
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>	

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
<i>[Handwritten mark]</i>	C355	Murray <i>et al.</i> , "Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer," <i>Journal of Pathology</i> , 185:256-261, 1998.
<i>[Handwritten mark]</i>	C356	Palyi <i>et al.</i> , "Effects of methylacetylenic putrescine, and ornithine decarboxylase inhibitor and potential novel anticancer agent, on human and mouse cancer cell lines," <i>Anti-Cancer Drugs</i> , 10:103-111, 1999.
<i>[Handwritten mark]</i>	C357	Pavicevic <i>et al.</i> , "Serum tumor marker CYFRA 21-1 in the diagnostics of NSCLC lung cancer," <i>Coll Antropol</i> , 22(2):629-635, 1998.
<i>[Handwritten mark]</i>	C358	Pavlik <i>et al.</i> , "Properties of anticancer agents relevant to in vitro determinations of human tumor cell sensitivity," <i>Cancer Chemother Pharmacol</i> , 11:8-15, 1983.
<i>[Handwritten mark]</i>	C359	Rasey <i>et al.</i> , "Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia," <i>Int J Radiation Oncology Biol Phys</i> , 17:985-991, 1989.
<i>[Handwritten mark]</i>	C360	Rasey <i>et al.</i> , "Characteristics of the binding of labeled fluoromisonidazole in cells in vitro," <i>Radiation Research</i> , 122:301-308, 1990.
<i>[Handwritten mark]</i>	C361	Reutelingsperger and van Heerde, "Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis," <i>Cell Mol Life Sci</i> , 53:527-532, 1997.
<i>[Handwritten mark]</i>	C362	Thompson, "Apoptosis in the pathogenesis and treatment of disease," <i>Science</i> , 267:1456-1462, 1995.
<i>[Handwritten mark]</i>	C363	Tolomeo <i>et al.</i> , "The CD95/CD95 ligand system is not the major effector in anticancer drug-mediated apoptosis," <i>Cell Death and Differentiation</i> , 5:735-742, 1998.
<i>[Handwritten mark]</i>	C364	Van den Eijnde <i>et al.</i> , "In situ detection of apoptosis during embryogenesis with annexin V: from whole mount to ultrastructure," <i>Cytometry</i> , 29:313-320, 1997.
<i>[Handwritten mark]</i>	C365	Wright <i>et al.</i> , "Aminoglycoside antibiotics: structures, functions, and resistance," In: <i>Resolving the Antibiotic Paradox</i> , Rosen and Mobashery eds, Kluwer Academic/Plenum Pub NY, 1998. <i>pp 27-69.</i>
<i>[Handwritten mark]</i>	C366	Yoshinari <i>et al.</i> , "Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I," <i>Cancer Res.</i> , 59:4271-4275, 1999.

25497767.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP § 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)